A phase 3 trial of bevacizumab in ovarian cancer.

@article{Perren2011AP3,
  title={A phase 3 trial of bevacizumab in ovarian cancer.},
  author={T. Perren and A. Swart and J. Pfisterer and J. Ledermann and {\'E}. Pujade-Lauraine and G. Kristensen and M. Carey and P. Beale and A. Cervantes and C. Kurzeder and A. Du Bois and J. Sehouli and R. Kimmig and A. St{\"a}hle and F. Collinson and S. Essapen and C. Gourley and A. Lortholary and F. Selle and M. Mirza and A. Leminen and M. Plante and D. Stark and W. Qian and M. Parmar and A. Oza},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 26},
  pages={
          2484-96
        }
}
BACKGROUND Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. METHODS We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every… Expand
1,076 Citations

Paper Mentions

Interventional Clinical Trial
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs… Expand
ConditionsAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
InterventionDrug
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
  • K. Tewari, R. Burger, +24 authors B. Monk
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019
  • 66
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
  • 1
  • PDF
Bevacizumab in ovarian cancer: A critical review of phase III studies
  • 58
  • Highly Influenced
  • PDF
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
  • 6
  • PDF
Critical appraisal of bevacizumab in the treatment of ovarian cancer
  • 19
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
  • 838
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
  • 703
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
  • M. Bookman, M. Brady, +13 authors L. M. Roth
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
  • 582
  • PDF
...
1
2
3
...